RE: CNBC's Kudlow & Kramer on biotechnology bigwind
if you think a person has to "reach further" to find things to be skeptical about onc, i think you are naive at best.
here are some points to ponder
1. they are running their cash position to very low levels - between 6 and 9 months and are planning to add another phase II systemic trial to their existing prostate & glio trials. that makes them susceptible to market manipulation - eg. if cannacord knows onc needs to raise funds, what prevents them from selling a wack of shares to drive the price down, forcing onc to issue more shares and allow cannacord to make more fees/commissions? of course, cannacord would never do something like that, would they?
2. despite all the talk here about imminent partnership, what major, reputable pharma is going to make an investment in the hundreds of millions (equity plus phase III trial costs) based on a sample of 6 removed prostate gland tumours treated with reolysin? imo, the reasonable answer is NONE, even if they can’t find any cancer cells remaining in the removed prostates, which interim results have already shown is not the case.
3. many here dismiss trial delays such as the recent 6 month glio halt without even knowing the specific reasons for the halt - the reason given in the press release was incredibly vague at best, leaving a lot of room for speculation.
the only facts that could be gleaned were that they suspended ph I enrolment to change the protocol - to suggest that it was to enhance measurement of efficacy yet suspend the phase I saftey portion of the trial raises enough yellow flags for me and i think most reasonably intelligent adults to be more cautious about such a halt. anyone who at this point even suggests, never mind emphatically states, that similar additional delays are impossible, or that great final results are guaranteed is a fool.
4. if a glio or prostate patient for that matter was searching for clinical trials to possibly participate or enrol in, they would not find onc's trials listed on the main Canadian or US web sites.
if you don't believe me, check out these links.
https://www.cancer.ca/ccs/internet/standard/0,3182,3172_14039__langId-en,00.html
https://www.cancer.gov/ClinicalTrials/
is that because onc already has more than enough enrollee applicants from word of mouth? - based on the number of enrollees to date in both trials, imo, thats another stretch that simply gets dismissed here.
Yes, reolysin appears promising – that’s why I am here, but to suggest that it’s a sure thing at this stage, without considering the above, is simply stupid.
But if you insist on hyping things or suggesting you have the real “inside scoop” leaving us "peons groping in the dark", I’ll gladly take profits from any resulting price spikes and buy back in cheaper when reality sets back in.